Premium
Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization
Author(s) -
SaundersPullman Rachel,
Hagenah Johann,
Dhawan Vijay,
Stanley Kaili,
Pastores Gregory,
Sathe Swati,
Tagliati Michele,
Condefer Kelly,
Palmese Christina,
Brüggemann Norbert,
Klein Christine,
Roe AM,
Kornreich Ruth,
Ozelius Laurie,
Bressman Susan
Publication year - 2010
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.23046
Subject(s) - parkinsonism , medicine , substantia nigra , dementia , dystonia , lewy body , pathology , parkinson's disease , neuropsychology , hyposmia , hypermetabolism , compound heterozygosity , dementia with lewy bodies , psychology , disease , psychiatry , mutation , biology , cognition , genetics , covid-19 , infectious disease (medical specialty) , gene
Among the genes implicated for parkinsonism is glucocerebrosidase (GBA), which causes Gaucher disease (GD). Despite a growing literature that GD may present as parkinsonism, neuroimaging, olfaction, and neuropsychological testing have not been extensively reported. We describe transcranial sonography (TCS), 18F‐fluorodopa (F‐dopa) and fluorodeoxyglucose (FDG) Positron emission tomography, olfaction testing, neuropsychological testing, and clinical features in homozygous and compound heterozygous GBA mutation carriers identified through screening of 250 Ashkenazi Jewish parkinsonian individuals treated at a tertiary care center. We identified two individuals with N370S/R496H compound heterozygous mutations and two with N370S homozygous mutations; one individual died before completing detailed evaluation. TCS (n = 3) demonstrated nigral hyperechogenicity that was greater than controls [median area maximal substantia nigra echogenicity (aSNmax) = 0.28 cm 2 vs. 0.14 cm 2 , P = 0.005], but similar to idiopathic PD (aSNmax = 0.31 cm 2 ). FDG PET (n = 2) demonstrated hypermetabolism of the lentiform nuclei, and F‐fluorodopa PET (n = 2), bilateral reduction in striatal F‐dopa uptake. Olfaction was markedly impaired in the two tested cases, including onset of smell disturbance in adolescence in one. Neuropsychological features (n = 3) were consistent with Parkinson's disease (PD) or diffuse Lewy body disease (DLB). The imaging, neuropsychological and olfactory markers suggest the GD phenotype includes PD with and without features of DLB, marked olfactory loss, nigral hyperechogenicity on TCS, and F‐dopa and FDG PET abnormalities. © 2010 Movement Disorder Society